NCT02673398
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 60 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Adult)s under the age 60; Patients with untreated unstable brain metastasis – see trial for details
https://ClinicalTrials.gov/show/NCT02673398